CompletedNot applicableNCT03477149
EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications
Studying Non-malignant and non-cirrhotic portal vein thrombosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Principal Investigator
- Marc SAPOVAL, MD, PhDAP-HP - Hôpital Européen Georges Pompidou
- Intervention
- Easyx(device)
- Enrollment
- 50 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2020
Study locations (1)
- AP-HP - Hopital Europeen Georges-Pompidou Paris, France, Paris, Île-de-France Region, France
Collaborators
Antia Therapeutics AG
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03477149 on ClinicalTrials.govOther trials for Non-malignant and non-cirrhotic portal vein thrombosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06500403Non-invasive Tools for PSVD DiagnosisNanfang Hospital, Southern Medical University
- RECRUITINGNCT06145100Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)University Hospital Freiburg
See all trials for Non-malignant and non-cirrhotic portal vein thrombosis →